Mosaic ImmunoEngineering (CPMV) Liabilities from Discontinued Operations (2011 - 2012)
Mosaic ImmunoEngineering (CPMV) posted quarterly Liabilities from Discontinued Operations of 231379.0 for Q1 2012, up 7.21% quarter-over-quarter from 215824.0 in Q2 2011.
Mosaic ImmunoEngineering (CPMV) Liabilities from Discontinued Operations (2011 - 2012) Analysis & Trends
Mosaic ImmunoEngineering's Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 231379.0 for Q1 2012.
- In Q1 2012, Liabilities from Discontinued Operations changed N/A year-over-year to 231379.0; the TTM figure through Feb 2012 stood at 231379.0 (changed N/A YoY), while the FY2011 annual figure was 215824.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2012 stood at 231379.0, up from 215824.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 231379.0 in Q1 2012, with the low at 215824.0 in Q2 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 29, 2012 | 231,379.00 |
| Feb 29, 2012 | 231,379.00 |
| May 31, 2011 | 215,824.00 |
| May 31, 2011 | 215,824.00 |